News
VTVT
35.70
-7.12%
-2.74
vTv Therapeutics: Buy Rating Reiterated on Favorable Risk-Reward and Clinical Momentum; $67 Price Target Unchanged
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT), Waters (WAT) and Alpha Teknova (TKNO)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT), Brookdale Senior Living (BKD) and Longeveron (LGVN)
TipRanks · 1d ago
Analyst Maintains Buy on vTv Therapeutics, Reiterates Unchanged $49 Price Target Amid Progress of Cadisegliatin Program
TipRanks · 1d ago
VTV THERAPEUTICS, INC. <VTVT.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $45 FROM $47
Reuters · 1d ago
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Reuters · 2d ago
Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA) and vTv Therapeutics (VTVT)
TipRanks · 2d ago
vTv Therapeutics Expands At-The-Market Share Program Capacity
TipRanks · 2d ago
VTV THERAPEUTICS INC - INCREASES CLASS A COMMON STOCK OFFERED UNDER ATM PROGRAM TO FULL AMOUNT - SEC FILING
Reuters · 2d ago
vTv Therapeutics boosts share capacity under at-the-market equity sales program
PUBT · 2d ago
vTv Therapeutics posts Q1 profit on license payment
Reuters · 2d ago
vTv Therapeutics Q1 FY26 swings to net income of $24.13 million; revenue $36.84 million
PUBT · 2d ago
VTV THERAPEUTICS Q1 OPERATING INCOME USD 23.263 MILLION
Reuters · 2d ago
*vTv Therapeutics 1Q EPS $1.65 >VTVT
Dow Jones · 2d ago
VTv Therapeutics: Q1 Earnings Snapshot
Barchart · 2d ago
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Barchart · 2d ago
Weekly Report: what happened at VTVT last week (0504-0508)?
Weekly Report · 4d ago
vTv Therapeutics grants 39,500 inducement stock options at $32 exercise price
PUBT · 05/08 20:17
vTv Therapeutics to present at H.C. Wainwright BioConnect investor conference
PUBT · 05/07 12:09
More
Webull provides a variety of real-time VTVT stock news. You can receive the latest news about Vtv Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.